acut
respiratori
infect
ari
one
main
caus
morbid
mortal
around
world
aim
studi
determin
frequenc
mortal
associ
clinic
entiti
influenza
viru
type
influenza
viru
type
b
respiratori
syncyti
viru
rsv
coronaviru
adenovirus
patient
ari
materi
method
septemb
till
may
respiratori
inpati
sampl
viral
test
collect
central
hospit
northwest
iran
realtim
revers
transcriptionpcr
rtpcr
assay
done
allow
one
test
detect
influenza
virus
also
rsv
adenoviru
identifi
immunochromatographi
test
result
twentyfour
case
posit
influenza
subtyp
case
subtyp
also
case
posit
influenza
b
case
posit
rsv
case
posit
adenoviru
one
patient
posit
influenza
adenoviru
two
patient
posit
influenza
rsv
none
patient
posit
coronaviru
conclus
find
show
import
influenza
viru
type
influenza
viru
type
b
rsv
adenovirus
associ
ari
hospit
patient
differ
epidemiolog
pattern
virus
tabriz
iran
acut
respiratori
infect
ari
caus
influenza
viru
type
subtyp
influenza
viru
type
b
respiratori
syncyti
viru
rsv
coronaviru
adenoviru
major
caus
upper
lower
respiratori
tract
diseas
infant
young
children
caus
croup
bronchiol
pneumonia
ari
one
main
caus
morbid
mortal
around
world
howev
due
social
nutrit
environment
factor
risk
death
due
ari
time
higher
develop
countri
northern
hemispher
rare
caus
death
industri
countri
ari
caus
enorm
direct
indirect
health
care
cost
rel
larg
proport
sampl
obtain
person
suffer
ari
pathogen
detect
despit
use
wide
rang
sensit
diagnost
assay
even
comprehens
studi
caus
agent
either
viral
nonvir
identifi
patient
accord
report
caus
million
annual
death
children
year
percent
hospit
children
health
center
associ
acut
respiratori
infect
major
outbreak
influenza
alway
associ
influenza
viru
type
b
especi
influenza
type
viru
account
four
worldwid
pandem
twentieth
centuri
due
viru
evolut
migrat
transmiss
respiratori
virus
anim
human
sever
matter
influenza
viru
infect
highli
contagi
respiratori
diseas
spread
easili
droplet
nasal
secret
respons
consider
morbid
mortal
estim
influenza
virus
caus
death
approxim
half
million
individu
worldwid
everi
year
associ
ill
among
age
group
risk
seriou
ill
death
follow
infect
highest
among
person
age
year
person
certain
chronic
medic
condit
also
rsv
known
tendenc
articl
publish
origin
caus
bronchiol
infanc
infect
agegroup
caus
ill
indistinguish
influenza
although
rsv
infect
import
viral
caus
sever
acut
lower
respiratori
tract
infect
small
proport
children
infect
viru
develop
sever
diseas
increas
understand
viru
host
respons
result
expand
therapeut
prevent
option
adenovirus
also
produc
varieti
seriou
diseas
peopl
age
mode
transmiss
adenoviru
infect
includ
respiratori
fomit
droplet
vener
faecalor
rout
shown
spread
eas
aid
patient
young
children
hospit
patient
constant
rate
worldwid
report
viru
infect
observ
due
adenoviru
infect
case
coronaviru
mani
isol
report
caus
upper
respiratori
tract
infect
children
adult
coronavirus
caus
wheez
young
asthmat
children
rare
caus
wheez
normal
children
determin
etiolog
diagnos
patient
admit
hospit
respiratori
symptom
remain
clinic
laboratori
challeng
infect
respiratori
viral
infect
tradit
diagnos
use
viral
cultur
rapid
antigen
test
direct
immunofluoresc
dif
test
howev
last
decad
nucleic
acid
amplif
techniqu
particularli
realtim
pcr
becom
avail
diagnost
tool
due
high
sensit
rapid
turnaround
time
aim
present
studi
determin
frequenc
mortal
viral
respiratori
infect
includ
influenza
viru
type
influenza
viru
type
b
respiratori
syncyti
viru
rsv
coronaviru
adenovirus
patient
ari
refer
central
hospit
northwest
iran
septemb
till
may
septemb
till
may
respiratori
specimen
viral
test
collect
central
hospit
tabriz
northwest
iran
specimen
includ
nasal
wash
salin
nasal
nasopharyng
swab
viral
transport
medium
bronchoalveolar
lavag
throat
oropharyng
swab
tracheal
aspir
sputum
patient
select
consecut
sampl
includ
two
respiratori
sampl
collect
special
sampl
collect
tube
patient
acut
onset
respiratori
symptom
accompani
fever
recent
travel
histori
countri
sustain
humantohuman
transmiss
rsv
coronaviru
adenoviru
influenza
viru
type
b
analyz
assay
obtain
written
inform
consent
parent
collect
demograph
data
inform
natur
cours
ill
medic
complic
durat
stay
parent
absente
followup
inform
inform
supplement
review
medic
record
structur
telephon
interview
data
collect
hospit
databas
includ
number
referr
central
hospit
northwest
iran
number
acut
admiss
discharg
diagnos
referr
admiss
realtim
rtpcr
done
base
protocol
viral
rna
extract
clinic
specimen
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
test
sampl
posit
neg
control
realtim
readi
rna
viru
master
kit
roch
germani
prepar
ad
viral
rna
mix
onestep
realtim
rtpcr
perform
accord
follow
condit
revers
transcript
minut
follow
cycl
cycl
use
rotorgen
corbett
research
sydney
australia
analyz
use
softwar
rotergen
version
corbett
australia
primer
probe
use
describ
protocol
rsv
adenoviru
identifi
corisbio
concept
immonochromatographi
diagnosi
test
cori
bioconcept
gembloux
belgium
detect
swab
nasopharyng
secret
everi
sampl
dilut
test
buffer
strip
ad
final
result
compar
posit
control
rsv
respiratori
adenoviru
posit
control
provid
corisbioconcept
also
sampl
suspect
patient
coronaviru
sent
center
infect
control
identifi
allel
specif
rtpcr
method
ministri
health
tehran
iran
data
analyz
test
fisher
exact
test
spss
version
use
statist
analysi
patient
refer
central
hospit
northwest
iran
period
case
obtain
femal
case
obtain
male
patient
investig
clinic
sign
viral
infect
posit
includ
radiograph
sign
fever
etc
among
suspect
patient
sampl
neg
virus
studi
sampl
posit
least
one
viru
distribut
sampl
accord
sex
presenc
viral
agent
shown
tabl
fifti
case
suspect
patient
older
sixti
case
case
younger
year
old
posit
case
sixteen
case
older
sixti
case
case
younger
year
old
also
case
suspect
patient
die
case
belong
neg
result
virus
case
dead
one
older
sixti
year
old
rest
year
old
three
case
posit
result
posit
virus
first
one
posit
adenovirus
second
one
posit
adenovirus
third
one
posit
rsv
among
case
posit
virus
one
die
among
posit
result
case
younger
year
old
male
posit
rsv
sixti
six
case
suspect
patient
live
tabriz
case
live
countrysid
case
live
turkey
six
suspici
patient
coronaviru
one
posit
also
signific
relationship
presenc
viral
agent
posit
bacteri
cultur
p
studi
show
among
case
respiratori
infect
case
posit
influenza
subtyp
case
subtyp
also
case
posit
influenza
b
case
rsv
adenoviru
case
posit
respect
spite
virus
posit
result
observ
coronaviru
reveal
import
mention
virus
associ
ari
hospit
patient
differ
epidemiolog
pattern
tabriz
iran
studi
carri
kerman
provinc
reveal
specimen
case
infect
adenoviru
case
rsv
rate
slightli
higher
result
obtain
studi
may
studi
conduct
children
year
anoth
studi
conduct
tehran
hospit
children
acut
respiratori
infect
influenza
viru
rsv
adenoviru
detect
respect
detect
season
influenza
virus
use
rtpcr
assay
flu
pandem
golestan
provinc
show
infect
season
influenza
season
influenza
studi
rate
infect
season
similar
studi
report
iran
lower
rate
report
part
world
survey
conduct
influenza
pandem
show
confirm
case
death
occur
howev
mortal
rate
studi
suspect
patient
among
virus
acut
respiratori
tract
infect
respons
consider
morbid
mortal
human
anim
cost
attribut
acut
respiratori
tract
ill
human
import
burden
nation
health
care
budget
morbid
mortal
influenza
rsv
vari
year
year
commun
commun
institut
institut
accur
estim
diseas
burden
requir
tempor
geograph
institut
breadth
accord
latest
data
influenza
least
death
relat
pandem
report
nearli
report
region
offic
eastern
mediterranean
emro
studi
respiratori
viru
detect
among
children
hospit
respiratori
ill
differ
part
world
rsv
influenza
frequent
associ
substanti
proport
hospit
although
human
adenoviru
infect
less
common
adult
respiratori
viru
infect
influenza
virus
human
rhinovirus
human
parainfluenza
virus
enterovirus
human
coronavirus
caus
fatal
respiratori
tract
infect
affect
patient
influenza
occur
world
annual
global
attack
rate
estim
adult
children
temper
region
influenza
season
diseas
occur
typic
winter
month
affect
northern
hemispher
novemb
april
peak
februari
southern
hemispher
april
septemb
cor
relat
influenza
activ
climat
previous
suggest
countri
vaccin
remain
import
mean
reduc
morbid
mortal
caus
influenza
virus
influenza
viru
caus
pandem
continu
circul
part
world
caus
variabl
level
diseas
outbreak
countri
season
trival
vaccin
avail
cover
viru
countri
howev
season
influenza
vaccin
avail
advis
still
public
health
valu
use
monoval
vaccin
avail
immun
person
risk
sever
diseas
influenza
infect
especi
trival
season
influenza
vaccin
avail
howev
individu
vaccin
vaccin
avail
antivir
agent
provid
import
altern
group
increas
risk
sever
ill
pandem
viru
includ
young
children
pregnant
women
peopl
underli
respiratori
chronic
condit
includ
asthma
diabet
patient
sever
deterior
influenza
treat
soon
possibl
oseltamivir
patient
higher
risk
sever
complic
influenza
treat
oseltamivir
zanamivir
soon
possibl
travel
like
local
resid
risk
influenza
season
addit
group
travel
eg
cruis
ship
includ
individu
area
affect
season
influenza
may
experi
outofseason
outbreak
travel
visit
countri
opposit
hemispher
influenza
season
special
risk
particularli
degre
immun
recent
infect
regular
vaccin
studi
almost
half
patient
live
small
town
rural
area
differ
climat
condit
differ
preval
viral
diseas
patient
often
refer
treatment
central
hospit
northwest
iran
may
role
transmiss
diseas
new
area
given
nonspecif
symptom
virus
high
preval
viral
diarrhea
region
laboratori
equip
viru
detect
vaccin
might
consid
prevent
strategi
detect
influenza
virus
pcr
method
wide
use
materi
equip
avail
mani
countri
howev
rate
mutat
ha
na
gene
influenza
viru
high
therefor
determin
subtyp
use
specif
primer
suggest
cdc
also
realtim
pcr
consider
increas
diagnost
yield
respiratori
virus
patient
admit
respiratori
symptom
within
clinic
relev
time
frame
allow
clinician
initi
optim
patient
manag
initi
adequ
futur
use
antivir
therapi
optim
infect
control
therefor
conclud
spite
gener
concept
virus
investig
studi
shown
endem
distribut
among
studi
period
spread
rumor
ebola
diseas
outbreak
social
network
wave
fear
peopl
similar
even
mild
symptom
creat
howev
lastli
consid
epidem
influenza
possibl
coronaviru
b
result
indic
rapid
test
method
use
present
studi
show
less
posit
result
compar
rtpcr
method
c
case
influenza
b
mortal
influenza
possibl
contrari
other
final
conclud
need
develop
local
protocol
strategi
case
viral
infect
act
face
microepidem
endem
prevent
distribut
infect
